Tag: form

NEW YORK, June 26, 2026 (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds investors who purchased Erasca, Inc. (“Erasca” or the “Company”) (NASDAQ:ERAS) securities to contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests in the securities fraud class action lawsuit at no cost.

NEW YORK, June 26, 2026 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced that Space Exploration Technologies Corporation (Nasdaq: SPCX) will become a component of the Nasdaq-100 Index® prior to market open on Tuesday, July 7, 2026.

NEW YORK, June 26, 2026 (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds investors who purchased ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ:ADMA) securities to contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests in the securities fraud class action lawsuit at no cost.

NEW YORK, June 26, 2026 (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds investors who purchased Nano-X Imaging Ltd. (“Nano-X” or the “Company”) (NASDAQ:NNOX) securities to contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests in the securities fraud class action lawsuit at no cost.

LIKMEZ® (ATI-1501) commercial momentum building in U.S. market

US$40 million NIAID award supporting VXV-01 advancement through Phase 1

NEW YORK, June 26, 2026 (GLOBE NEWSWIRE) -- 21shares, one of the world’s largest issuers of cryptocurrency exchange traded products (ETPs), today announced the following shareholder distributions for the 21shares Ethereum ETF (TETH), 21shares Solana ETF (TSOL), 21shares Hyperliquid ETF (THYP), 21shares Sui ETF (TSUI), and 21shares Polkadot ETF (TDOT). Distributions consist of staking rewards earned from staked ETH, SOL, HYPE, SUI, and DOT tokens by each fund, respectively.

BEDMINSTER, N.J., June 26, 2026 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (the “Company”) (NYSE American: MTNB) announced today that on June 24, 2026, it received a notice (the “Notice”) from the NYSE American LLC (the “NYSE American”) stating that the Company is not in compliance with the NYSE American continued listing standards set forth in Section 1003(a)(ii) of the NYSE American Company Guide (the “Company Guide”) requiring a company to have stockholders’ equity of at least $4.0 million if it has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. As of March 31, 2026, the Company had stockholders’ equity of $3.02 million and has had losses in the most recent five fiscal years ended December 31, 2025. As previously disclosed, the Company is also not in compliance with Section 1003(a)(iii) of the Company Guide requiring a company to have stockholders’ equity of at least $6.0 million if it has reported losses from continuing operations and/or net losses in its five most recent fiscal years. As of December 31, 2025, the Company had stockholders’ equity of $4.83 million and has had losses in the most recent five fiscal years ended December 31, 2025. Due to its non-compliance with Sections 1003(a)(ii) and 1003(a)(iii) of the Company Guide, the Company is subject to the procedures and requirements of Section 1009 of the Company Guide.